clonidine	alcohol	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	none	D003000	none
clonidine	alcohol	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	none	D003000	none
clonidine	alcohol	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	none	D003000	none
clonidine	alcohol	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	none	D003000	none
clonidine	Verapamil	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	Verapamil	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	Verapamil	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	Verapamil	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	Verapamil	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	Verapamil	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	Verapamil	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		2599	11170	D003000	11170
clonidine	Verapamil	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		2599	11170	D003000	11170
clonidine	Verapamil	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	Verapamil	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	Verapamil	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	Verapamil	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	Verapamil	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	Verapamil	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	Verapamil	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	Verapamil	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	digoxin	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	3407	D003000	3407
clonidine	digoxin	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	3407	D003000	3407
clonidine	Telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
clonidine	Telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
clonidine	Telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
clonidine	Telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
clonidine	verapamil	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	verapamil	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	verapamil	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	verapamil	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	verapamil	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	verapamil	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	verapamil	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		2599	11170	D003000	11170
clonidine	verapamil	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		2599	11170	D003000	11170
clonidine	verapamil	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	verapamil	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	verapamil	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	verapamil	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	verapamil	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	verapamil	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	11170	D003000	11170
clonidine	verapamil	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	verapamil	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	11170	D003000	11170
clonidine	ethanol	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	448	D003000	D000431
clonidine	ethanol	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		2599	448	D003000	D000431
clonidine	ethanol	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	448	D003000	D000431
clonidine	ethanol	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		2599	448	D003000	D000431
clonidine	Clonidine	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		D003000	D003000
clonidine	Clonidine	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		D003000	D003000
clonidine	Clonidine	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		D003000	D003000
clonidine	Clonidine	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		D003000	D003000
clonidine	telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
clonidine	telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
clonidine	telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
clonidine	telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
clonidine	doxorubicin	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		2599	3639	D003000	3639
clonidine	doxorubicin	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		2599	3639	D003000	3639
curare	Verapamil	55	55	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		none	11170	D003472	11170
curare	Verapamil	55	55	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		none	11170	D003472	11170
curare	Verapamil	55	54	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		none	11170	D003472	11170
curare	Verapamil	55	54	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		none	11170	D003472	11170
curare	Verapamil	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		none	11170	D003472	11170
curare	Verapamil	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		none	11170	D003472	11170
curare	Verapamil	55	56	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		none	11170	D003472	11170
curare	Verapamil	55	56	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		none	11170	D003472	11170
curare	verapamil	55	55	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		none	11170	D003472	11170
curare	verapamil	55	55	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		none	11170	D003472	11170
curare	verapamil	55	54	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		none	11170	D003472	11170
curare	verapamil	55	54	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		none	11170	D003472	11170
curare	verapamil	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		none	11170	D003472	11170
curare	verapamil	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		none	11170	D003472	11170
curare	verapamil	55	56	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		none	11170	D003472	11170
curare	verapamil	55	56	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		none	11170	D003472	11170
curare	Phenobarbital	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		none	8134	D003472	D010634
curare	Phenobarbital	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		none	8134	D003472	D010634
cisplatin	quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		2555	9068	2555	9068
cisplatin	quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		2555	9068	2555	9068
cisplatin	cyclophosphamide	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	3002	2555	D003520
cisplatin	cyclophosphamide	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	3002	2555	D003520
cisplatin	adriamycin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	0	2555	42512
cisplatin	adriamycin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	0	2555	42512
cisplatin	Verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11170	2555	11170
cisplatin	Verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11170	2555	11170
cisplatin	Verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		2555	11170	2555	11170
cisplatin	Verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		2555	11170	2555	11170
cisplatin	Verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11170	2555	11170
cisplatin	Verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11170	2555	11170
cisplatin	Verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		2555	11170	2555	11170
cisplatin	Verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		2555	11170	2555	11170
cisplatin	vindesine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11204	2555	11204
cisplatin	vindesine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11204	2555	11204
cisplatin	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	274786	2555	274786
cisplatin	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	274786	2555	274786
cisplatin	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11170	2555	11170
cisplatin	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11170	2555	11170
cisplatin	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		2555	11170	2555	11170
cisplatin	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		2555	11170	2555	11170
cisplatin	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11170	2555	11170
cisplatin	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11170	2555	11170
cisplatin	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		2555	11170	2555	11170
cisplatin	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		2555	11170	2555	11170
cisplatin	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	274786	2555	274786
cisplatin	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	274786	2555	274786
cisplatin	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		2555	56946	2555	56946
cisplatin	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		2555	56946	2555	56946
cisplatin	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	8702	2555	8702
cisplatin	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	8702	2555	8702
cisplatin	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		2555	9068	2555	9068
cisplatin	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		2555	9068	2555	9068
cisplatin	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	3639	2555	3639
cisplatin	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	3639	2555	3639
cisplatin	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	8640	2555	D011241
cisplatin	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	8640	2555	D011241
cisplatin	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11202	2555	D014750
cisplatin	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		2555	11202	2555	D014750
timolol	propranolol	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		0	8787	D013999	D011433
timolol	propranolol	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		0	8787	D013999	D011433
timolol	Verapamil	17	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  		0	11170	D013999	11170
timolol	Verapamil	17	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  		0	11170	D013999	11170
timolol	Verapamil	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		0	11170	D013999	11170
timolol	Verapamil	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		0	11170	D013999	11170
timolol	Verapamil	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		0	11170	D013999	11170
timolol	Verapamil	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		0	11170	D013999	11170
timolol	atenolol	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		0	1202	D013999	D001262
timolol	atenolol	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		0	1202	D013999	D001262
timolol	verapamil	17	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  		0	11170	D013999	11170
timolol	verapamil	17	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  		0	11170	D013999	11170
timolol	verapamil	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		0	11170	D013999	11170
timolol	verapamil	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		0	11170	D013999	11170
timolol	verapamil	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		0	11170	D013999	11170
timolol	verapamil	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		0	11170	D013999	11170
timolol	metoprolol	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		0	6918	D013999	D008790
timolol	metoprolol	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		0	6918	D013999	D008790
quinidine	cyclophosphamide	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	3002	9068	D003520
quinidine	cyclophosphamide	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	3002	9068	D003520
quinidine	adriamycin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	0	9068	42512
quinidine	adriamycin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	0	9068	42512
quinidine	Aspirin	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	1191	9068	1191
quinidine	Aspirin	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	1191	9068	1191
quinidine	Aspirin	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	1191	9068	1191
quinidine	Aspirin	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	1191	9068	1191
quinidine	Verapamil	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	Verapamil	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	Verapamil	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	Verapamil	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	Verapamil	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	Verapamil	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	Verapamil	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	Verapamil	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	Verapamil	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	Verapamil	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	Verapamil	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	Verapamil	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	Verapamil	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	Verapamil	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	Verapamil	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	11170	9068	11170
quinidine	Verapamil	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	11170	9068	11170
quinidine	Verapamil	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	38	40	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		9068	11170	9068	11170
quinidine	Verapamil	38	40	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		9068	11170	9068	11170
quinidine	Verapamil	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	Verapamil	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	Verapamil	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	11170	9068	11170
quinidine	Verapamil	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	11170	9068	11170
quinidine	Verapamil	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	Verapamil	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	aspirin	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	1191	9068	1191
quinidine	aspirin	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	1191	9068	1191
quinidine	aspirin	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	1191	9068	1191
quinidine	aspirin	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	1191	9068	1191
quinidine	vindesine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11204	9068	11204
quinidine	vindesine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11204	9068	11204
quinidine	verapamil	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	verapamil	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	verapamil	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	verapamil	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	verapamil	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	verapamil	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	verapamil	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	verapamil	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11170	9068	11170
quinidine	verapamil	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	verapamil	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	verapamil	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	verapamil	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	verapamil	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	verapamil	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	11170	9068	11170
quinidine	verapamil	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	11170	9068	11170
quinidine	verapamil	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	11170	9068	11170
quinidine	verapamil	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	38	40	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		9068	11170	9068	11170
quinidine	verapamil	38	40	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		9068	11170	9068	11170
quinidine	verapamil	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	11170	9068	11170
quinidine	verapamil	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	11170	9068	11170
quinidine	verapamil	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	11170	9068	11170
quinidine	verapamil	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		9068	11170	9068	11170
quinidine	verapamil	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	verapamil	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	11170	9068	11170
quinidine	paclitaxel	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	56946	9068	56946
quinidine	paclitaxel	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	56946	9068	56946
quinidine	paclitaxel	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	56946	9068	56946
quinidine	paclitaxel	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	56946	9068	56946
quinidine	procarbazine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	8702	9068	8702
quinidine	procarbazine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	8702	9068	8702
quinidine	Quinidine	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	9068
quinidine	Quinidine	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	9068
quinidine	Quinidine	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	9068
quinidine	Quinidine	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	9068
quinidine	Quinidine	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		9068	9068
quinidine	Quinidine	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	9068
quinidine	Quinidine	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	9068
quinidine	Quinidine	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		9068	9068
quinidine	Quinidine	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	9068
quinidine	Quinidine	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	9068
quinidine	Quinidine	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	9068
quinidine	Quinidine	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	9068
quinidine	Quinidine	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	9068
quinidine	Quinidine	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		9068	9068
quinidine	Quinidine	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	9068
quinidine	Quinidine	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	9068
quinidine	Quinidine	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		9068	9068
quinidine	Quinidine	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	9068
quinidine	Quinidine	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		9068	9068
quinidine	prednisone	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	8640	9068	D011241
quinidine	prednisone	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	8640	9068	D011241
quinidine	oncovin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11202	9068	D014750
quinidine	oncovin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11202	9068	D014750
cyclophosphamide	adriamycin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	0	D003520	42512
cyclophosphamide	adriamycin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	0	D003520	42512
cyclophosphamide	Verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11170	D003520	11170
cyclophosphamide	Verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11170	D003520	11170
cyclophosphamide	Verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		3002	11170	D003520	11170
cyclophosphamide	Verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		3002	11170	D003520	11170
cyclophosphamide	Verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11170	D003520	11170
cyclophosphamide	Verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11170	D003520	11170
cyclophosphamide	Verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		3002	11170	D003520	11170
cyclophosphamide	Verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		3002	11170	D003520	11170
cyclophosphamide	vindesine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11204	D003520	11204
cyclophosphamide	vindesine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11204	D003520	11204
cyclophosphamide	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	274786	D003520	274786
cyclophosphamide	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	274786	D003520	274786
cyclophosphamide	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11170	D003520	11170
cyclophosphamide	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11170	D003520	11170
cyclophosphamide	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		3002	11170	D003520	11170
cyclophosphamide	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		3002	11170	D003520	11170
cyclophosphamide	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11170	D003520	11170
cyclophosphamide	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11170	D003520	11170
cyclophosphamide	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		3002	11170	D003520	11170
cyclophosphamide	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		3002	11170	D003520	11170
cyclophosphamide	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	274786	D003520	274786
cyclophosphamide	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	274786	D003520	274786
cyclophosphamide	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		3002	56946	D003520	56946
cyclophosphamide	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		3002	56946	D003520	56946
cyclophosphamide	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	8702	D003520	8702
cyclophosphamide	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	8702	D003520	8702
cyclophosphamide	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		3002	9068	D003520	9068
cyclophosphamide	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		3002	9068	D003520	9068
cyclophosphamide	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	3639	D003520	3639
cyclophosphamide	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	3639	D003520	3639
cyclophosphamide	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	8640	D003520	D011241
cyclophosphamide	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	8640	D003520	D011241
cyclophosphamide	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11202	D003520	D014750
cyclophosphamide	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3002	11202	D003520	D014750
adriamycin	Verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11170	42512	11170
adriamycin	Verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11170	42512	11170
adriamycin	Verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		0	11170	42512	11170
adriamycin	Verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		0	11170	42512	11170
adriamycin	Verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11170	42512	11170
adriamycin	Verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11170	42512	11170
adriamycin	Verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		0	11170	42512	11170
adriamycin	Verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		0	11170	42512	11170
adriamycin	vindesine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11204	42512	11204
adriamycin	vindesine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11204	42512	11204
adriamycin	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	274786	42512	274786
adriamycin	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	274786	42512	274786
adriamycin	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11170	42512	11170
adriamycin	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11170	42512	11170
adriamycin	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		0	11170	42512	11170
adriamycin	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		0	11170	42512	11170
adriamycin	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11170	42512	11170
adriamycin	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11170	42512	11170
adriamycin	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		0	11170	42512	11170
adriamycin	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		0	11170	42512	11170
adriamycin	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	274786	42512	274786
adriamycin	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	274786	42512	274786
adriamycin	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		0	56946	42512	56946
adriamycin	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		0	56946	42512	56946
adriamycin	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	8702	42512	8702
adriamycin	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	8702	42512	8702
adriamycin	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		0	9068	42512	9068
adriamycin	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		0	9068	42512	9068
adriamycin	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	3639	42512	3639
adriamycin	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	3639	42512	3639
adriamycin	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	8640	42512	D011241
adriamycin	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	8640	42512	D011241
adriamycin	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11202	42512	D014750
adriamycin	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		0	11202	42512	D014750
Flecainide	Disopyramide	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	3541	4441	D004206
Flecainide	Disopyramide	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	3541	4441	D004206
Flecainide	Disopyramide	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	3541	4441	D004206
Flecainide	Disopyramide	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	3541	4441	D004206
Flecainide	prazosin	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	8629	4441	D011224
Flecainide	prazosin	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	8629	4441	D011224
Flecainide	Verapamil	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	Verapamil	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	Verapamil	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
Flecainide	Verapamil	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
Flecainide	Verapamil	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	Verapamil	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	Verapamil	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	Verapamil	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	Verapamil	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	Verapamil	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	Verapamil	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	Verapamil	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	Verapamil	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
Flecainide	Verapamil	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
Flecainide	Verapamil	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	Verapamil	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	Verapamil	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	Verapamil	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	Carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		4441	2002	4441	D002220
Flecainide	Carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		4441	2002	4441	D002220
Flecainide	Carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
Flecainide	Carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
Flecainide	Carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
Flecainide	Carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
Flecainide	flecainide	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	4441
Flecainide	flecainide	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	4441
Flecainide	flecainide	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	4441
Flecainide	flecainide	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	4441
Flecainide	disopyramide	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	3541	4441	D004206
Flecainide	disopyramide	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	3541	4441	D004206
Flecainide	disopyramide	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	3541	4441	D004206
Flecainide	disopyramide	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	3541	4441	D004206
Flecainide	verapamil	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	verapamil	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	verapamil	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
Flecainide	verapamil	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
Flecainide	verapamil	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	verapamil	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	verapamil	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	verapamil	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	verapamil	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	verapamil	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	verapamil	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	verapamil	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
Flecainide	verapamil	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
Flecainide	verapamil	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
Flecainide	verapamil	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	verapamil	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	verapamil	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	verapamil	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
Flecainide	carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		4441	2002	4441	D002220
Flecainide	carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		4441	2002	4441	D002220
Flecainide	carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
Flecainide	carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
Flecainide	carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
Flecainide	carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
cimetidine	theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	10438	2541	D013806
cimetidine	theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	10438	2541	D013806
cimetidine	Verapamil	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	Verapamil	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	Verapamil	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	Verapamil	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	Verapamil	60	62	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		2541	11170	2541	11170
cimetidine	Verapamil	60	62	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		2541	11170	2541	11170
cimetidine	Verapamil	60	61	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		2541	11170	2541	11170
cimetidine	Verapamil	60	61	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		2541	11170	2541	11170
cimetidine	Verapamil	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	Verapamil	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	Rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	9384	2541	9384
cimetidine	Rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	9384	2541	9384
cimetidine	verapamil	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	verapamil	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	verapamil	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	verapamil	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	verapamil	60	62	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		2541	11170	2541	11170
cimetidine	verapamil	60	62	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		2541	11170	2541	11170
cimetidine	verapamil	60	61	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		2541	11170	2541	11170
cimetidine	verapamil	60	61	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		2541	11170	2541	11170
cimetidine	verapamil	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	verapamil	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	11170	2541	11170
cimetidine	rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	9384	2541	9384
cimetidine	rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	9384	2541	9384
cimetidine	Theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	10438	2541	D013806
cimetidine	Theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	10438	2541	D013806
cimetidine	Cimetidine	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		2541	2541
theophylline	Verapamil	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	Verapamil	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	Verapamil	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	Verapamil	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	Verapamil	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	Verapamil	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	Verapamil	59	61	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		10438	11170	D013806	11170
theophylline	Verapamil	59	61	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		10438	11170	D013806	11170
theophylline	Verapamil	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		10438	11170	D013806	11170
theophylline	Verapamil	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		10438	11170	D013806	11170
theophylline	Rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	9384	D013806	9384
theophylline	Rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	9384	D013806	9384
theophylline	verapamil	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	verapamil	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	verapamil	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	verapamil	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	verapamil	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	verapamil	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	11170	D013806	11170
theophylline	verapamil	59	61	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		10438	11170	D013806	11170
theophylline	verapamil	59	61	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		10438	11170	D013806	11170
theophylline	verapamil	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		10438	11170	D013806	11170
theophylline	verapamil	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		10438	11170	D013806	11170
theophylline	rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	9384	D013806	9384
theophylline	rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	9384	D013806	9384
theophylline	Theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		D013806	D013806
theophylline	Phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	8134	D013806	D010634
theophylline	Phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	8134	D013806	D010634
theophylline	Cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		10438	2541	D013806	2541
theophylline	Cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		10438	2541	D013806	2541
propranolol	Verapamil	18	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	11170	D011433	11170
propranolol	Verapamil	18	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	11170	D011433	11170
propranolol	Verapamil	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		8787	11170	D011433	11170
propranolol	Verapamil	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		8787	11170	D011433	11170
propranolol	Verapamil	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	11170	D011433	11170
propranolol	Verapamil	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	11170	D011433	11170
propranolol	Verapamil	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		8787	11170	D011433	11170
propranolol	Verapamil	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		8787	11170	D011433	11170
propranolol	digoxin	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		8787	3407	D011433	3407
propranolol	digoxin	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		8787	3407	D011433	3407
propranolol	atenolol	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		8787	1202	D011433	D001262
propranolol	atenolol	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		8787	1202	D011433	D001262
propranolol	verapamil	18	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	11170	D011433	11170
propranolol	verapamil	18	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	11170	D011433	11170
propranolol	verapamil	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		8787	11170	D011433	11170
propranolol	verapamil	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		8787	11170	D011433	11170
propranolol	verapamil	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	11170	D011433	11170
propranolol	verapamil	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	11170	D011433	11170
propranolol	verapamil	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		8787	11170	D011433	11170
propranolol	verapamil	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		8787	11170	D011433	11170
propranolol	digitalis	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		8787	none	D011433	none
propranolol	digitalis	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		8787	none	D011433	none
propranolol	metoprolol	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	6918	D011433	D008790
propranolol	metoprolol	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		8787	6918	D011433	D008790
Aspirin	Verapamil	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	Verapamil	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	Verapamil	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	Verapamil	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	Verapamil	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	Verapamil	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	Verapamil	39	40	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		1191	11170	1191	11170
Aspirin	Verapamil	39	40	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		1191	11170	1191	11170
Aspirin	aspirin	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	1191
Aspirin	verapamil	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	verapamil	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	verapamil	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	verapamil	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	verapamil	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	verapamil	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
Aspirin	verapamil	39	40	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		1191	11170	1191	11170
Aspirin	verapamil	39	40	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		1191	11170	1191	11170
Aspirin	Quinidine	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	9068	1191	9068
Aspirin	Quinidine	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	9068	1191	9068
Aspirin	Quinidine	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	9068	1191	9068
Aspirin	Quinidine	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	9068	1191	9068
Disopyramide	prazosin	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	8629	D004206	D011224
Disopyramide	prazosin	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	8629	D004206	D011224
Disopyramide	Verapamil	44	42	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	42	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		3541	11170	D004206	11170
Disopyramide	Verapamil	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		3541	11170	D004206	11170
Disopyramide	flecainide	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		3541	4441	D004206	4441
Disopyramide	flecainide	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		3541	4441	D004206	4441
Disopyramide	flecainide	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		3541	4441	D004206	4441
Disopyramide	flecainide	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		3541	4441	D004206	4441
Disopyramide	disopyramide	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		D004206	D004206
Disopyramide	verapamil	44	42	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	42	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		3541	11170	D004206	11170
Disopyramide	verapamil	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		3541	11170	D004206	11170
prazosin	Verapamil	43	42	true	positive	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		8629	11170	D011224	11170
prazosin	Verapamil	43	42	true	positive	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		8629	11170	D011224	11170
prazosin	Verapamil	43	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		8629	11170	D011224	11170
prazosin	Verapamil	43	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		8629	11170	D011224	11170
prazosin	Verapamil	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		8629	11170	D011224	11170
prazosin	Verapamil	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		8629	11170	D011224	11170
prazosin	Verapamil	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		8629	11170	D011224	11170
prazosin	Verapamil	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		8629	11170	D011224	11170
prazosin	flecainide	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		8629	4441	D011224	4441
prazosin	flecainide	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		8629	4441	D011224	4441
prazosin	disopyramide	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		8629	3541	D011224	D004206
prazosin	disopyramide	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		8629	3541	D011224	D004206
prazosin	verapamil	43	42	true	positive	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		8629	11170	D011224	11170
prazosin	verapamil	43	42	true	positive	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		8629	11170	D011224	11170
prazosin	verapamil	43	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		8629	11170	D011224	11170
prazosin	verapamil	43	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		8629	11170	D011224	11170
prazosin	verapamil	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		8629	11170	D011224	11170
prazosin	verapamil	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		8629	11170	D011224	11170
prazosin	verapamil	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		8629	11170	D011224	11170
prazosin	verapamil	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		8629	11170	D011224	11170
alcohol	Verapamil	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	11170	none	11170
alcohol	Verapamil	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	11170	none	11170
alcohol	Verapamil	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	11170	none	11170
alcohol	Verapamil	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	11170	none	11170
alcohol	Verapamil	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		none	11170	none	11170
alcohol	Verapamil	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		none	11170	none	11170
alcohol	Verapamil	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		none	11170	none	11170
alcohol	Verapamil	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		none	11170	none	11170
alcohol	digoxin	27	25	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	3407	none	3407
alcohol	digoxin	27	25	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	3407	none	3407
alcohol	digoxin	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	3407	none	3407
alcohol	digoxin	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	3407	none	3407
alcohol	verapamil	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	11170	none	11170
alcohol	verapamil	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	11170	none	11170
alcohol	verapamil	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	11170	none	11170
alcohol	verapamil	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	11170	none	11170
alcohol	verapamil	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		none	11170	none	11170
alcohol	verapamil	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		none	11170	none	11170
alcohol	verapamil	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		none	11170	none	11170
alcohol	verapamil	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		none	11170	none	11170
alcohol	ethanol	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	448	none	D000431
alcohol	ethanol	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		none	448	none	D000431
alcohol	Clonidine	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		none	2599	none	D003000
alcohol	Clonidine	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		none	2599	none	D003000
alcohol	Clonidine	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		none	2599	none	D003000
alcohol	Clonidine	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		none	2599	none	D003000
digitoxin	Verapamil	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	Verapamil	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	Verapamil	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	Verapamil	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	Verapamil	24	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	Verapamil	24	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	Verapamil	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3403	11170	D004074	11170
digitoxin	Verapamil	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3403	11170	D004074	11170
digitoxin	digoxin	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	3407	D004074	3407
digitoxin	digoxin	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	3407	D004074	3407
digitoxin	digoxin	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	3407	D004074	3407
digitoxin	digoxin	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	3407	D004074	3407
digitoxin	digoxin	24	25	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		3403	3407	D004074	3407
digitoxin	digoxin	24	25	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		3403	3407	D004074	3407
digitoxin	digoxin	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3403	3407	D004074	3407
digitoxin	digoxin	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3403	3407	D004074	3407
digitoxin	verapamil	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	verapamil	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	verapamil	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	verapamil	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	verapamil	24	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	verapamil	24	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	11170	D004074	11170
digitoxin	verapamil	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3403	11170	D004074	11170
digitoxin	verapamil	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3403	11170	D004074	11170
digitoxin	digitalis	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	none	D004074	none
digitoxin	digitalis	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3403	none	D004074	none
Verapamil	Carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	47	48	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	47	48	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	50	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	50	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	49	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	49	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
Verapamil	Carbamazepine	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
Verapamil	flecainide	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	4441	11170	4441
Verapamil	flecainide	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	4441	11170	4441
Verapamil	flecainide	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	4441	11170	4441
Verapamil	flecainide	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	4441	11170	4441
Verapamil	flecainide	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	4441	11170	4441
Verapamil	flecainide	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	4441	11170	4441
Verapamil	flecainide	47	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	4441	11170	4441
Verapamil	flecainide	47	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	4441	11170	4441
Verapamil	flecainide	47	45	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	4441	11170	4441
Verapamil	flecainide	47	45	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	4441	11170	4441
Verapamil	flecainide	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	4441	11170	4441
Verapamil	flecainide	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	4441	11170	4441
Verapamil	flecainide	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	4441	11170	4441
Verapamil	flecainide	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	4441	11170	4441
Verapamil	flecainide	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	4441	11170	4441
Verapamil	flecainide	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	4441	11170	4441
Verapamil	flecainide	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	4441	11170	4441
Verapamil	flecainide	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	4441	11170	4441
Verapamil	grapefruit	4	5	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	none	11170	none
Verapamil	grapefruit	4	5	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	none	11170	none
Verapamil	grapefruit	4	6	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	4	6	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	5	5	false	none	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	none	11170	none
Verapamil	grapefruit	5	5	false	none	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	none	11170	none
Verapamil	grapefruit	5	6	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	5	6	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	5	7	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	5	7	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	6	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	6	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	6	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	6	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	6	7	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	6	7	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	7	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	7	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	7	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	7	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	7	7	false	none	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	7	7	false	none	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	none	11170	none
Verapamil	grapefruit	7	9	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  		11170	none	11170	none
Verapamil	grapefruit	7	9	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  		11170	none	11170	none
Verapamil	grapefruit	8	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	8	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	8	7	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	8	7	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	none	11170	none
Verapamil	grapefruit	8	9	true	positive	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  		11170	none	11170	none
Verapamil	grapefruit	8	9	true	positive	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  		11170	none	11170	none
Verapamil	grapefruit	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	none
Verapamil	grapefruit	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	none
Verapamil	grapefruit	10	9	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	none
Verapamil	grapefruit	10	9	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	none
Verapamil	grapefruit	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	none
Verapamil	grapefruit	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	none
Verapamil	grapefruit	11	9	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	none	11170	none
Verapamil	grapefruit	11	9	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	none	11170	none
Verapamil	grapefruit	11	10	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	none	11170	none
Verapamil	grapefruit	11	10	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	none	11170	none
Verapamil	grapefruit	12	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	none	11170	none
Verapamil	grapefruit	12	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	none	11170	none
Verapamil	Rifampin	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
Verapamil	Rifampin	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
Verapamil	Rifampin	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
Verapamil	Rifampin	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
Verapamil	Rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	9384	11170	9384
Verapamil	Rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	9384	11170	9384
Verapamil	Rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	9384	11170	9384
Verapamil	Rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	9384	11170	9384
Verapamil	Rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	9384	11170	9384
Verapamil	Rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	9384	11170	9384
Verapamil	Rifampin	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	Rifampin	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	Rifampin	57	58	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	Rifampin	57	58	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	Rifampin	56	58	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	Rifampin	56	58	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	Rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	9384	11170	9384
Verapamil	Rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	9384	11170	9384
Verapamil	digoxin	19	21	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		11170	3407	11170	3407
Verapamil	digoxin	19	21	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		11170	3407	11170	3407
Verapamil	digoxin	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	3407	11170	3407
Verapamil	digoxin	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	3407	11170	3407
Verapamil	digoxin	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	3407	11170	3407
Verapamil	digoxin	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	3407	11170	3407
Verapamil	digoxin	20	21	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		11170	3407	11170	3407
Verapamil	digoxin	20	21	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		11170	3407	11170	3407
Verapamil	digoxin	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	3407	11170	3407
Verapamil	digoxin	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	3407	11170	3407
Verapamil	digoxin	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	3407	11170	3407
Verapamil	digoxin	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	3407	11170	3407
Verapamil	digoxin	23	21	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	3407	11170	3407
Verapamil	digoxin	23	21	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	3407	11170	3407
Verapamil	digoxin	23	23	false	none	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	3407	11170	3407
Verapamil	digoxin	23	23	false	none	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	3407	11170	3407
Verapamil	digoxin	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	3407	11170	3407
Verapamil	digoxin	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	3407	11170	3407
Verapamil	digoxin	23	25	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		11170	3407	11170	3407
Verapamil	digoxin	23	25	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		11170	3407	11170	3407
Verapamil	digoxin	22	21	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	3407	11170	3407
Verapamil	digoxin	22	21	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	3407	11170	3407
Verapamil	digoxin	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	3407	11170	3407
Verapamil	digoxin	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	3407	11170	3407
Verapamil	digoxin	22	23	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	3407	11170	3407
Verapamil	digoxin	22	23	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	3407	11170	3407
Verapamil	digoxin	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	3407	11170	3407
Verapamil	digoxin	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	3407	11170	3407
Verapamil	digoxin	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	3407	11170	3407
Verapamil	digoxin	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	3407	11170	3407
Verapamil	digoxin	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	3407	11170	3407
Verapamil	digoxin	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	3407	11170	3407
Verapamil	digoxin	24	25	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		11170	3407	11170	3407
Verapamil	digoxin	24	25	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		11170	3407	11170	3407
Verapamil	digoxin	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	3407	11170	3407
Verapamil	digoxin	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	3407	11170	3407
Verapamil	digoxin	27	25	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	3407	11170	3407
Verapamil	digoxin	27	25	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	3407	11170	3407
Verapamil	digoxin	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	3407	11170	3407
Verapamil	digoxin	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	3407	11170	3407
Verapamil	digoxin	26	25	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	3407	11170	3407
Verapamil	digoxin	26	25	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	3407	11170	3407
Verapamil	digoxin	26	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	3407	11170	3407
Verapamil	digoxin	26	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	3407	11170	3407
Verapamil	digoxin	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	3407	11170	3407
Verapamil	digoxin	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	3407	11170	3407
Verapamil	atenolol	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	1202	11170	D001262
Verapamil	atenolol	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	1202	11170	D001262
Verapamil	atenolol	19	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  		11170	1202	11170	D001262
Verapamil	atenolol	19	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  		11170	1202	11170	D001262
Verapamil	atenolol	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	1202	11170	D001262
Verapamil	atenolol	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	1202	11170	D001262
Verapamil	atenolol	20	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	1202	11170	D001262
Verapamil	atenolol	20	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	1202	11170	D001262
Verapamil	aspirin	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	1191	11170	1191
Verapamil	aspirin	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	1191	11170	1191
Verapamil	aspirin	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	1191	11170	1191
Verapamil	aspirin	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	1191	11170	1191
Verapamil	aspirin	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	1191	11170	1191
Verapamil	aspirin	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	1191	11170	1191
Verapamil	aspirin	40	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	1191	11170	1191
Verapamil	aspirin	40	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	1191	11170	1191
Verapamil	disopyramide	42	44	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	3541	11170	D004206
Verapamil	disopyramide	42	44	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	3541	11170	D004206
Verapamil	disopyramide	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	3541	11170	D004206
Verapamil	disopyramide	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	3541	11170	D004206
Verapamil	disopyramide	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	3541	11170	D004206
Verapamil	disopyramide	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	3541	11170	D004206
Verapamil	disopyramide	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	3541	11170	D004206
Verapamil	disopyramide	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	3541	11170	D004206
Verapamil	disopyramide	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	3541	11170	D004206
Verapamil	disopyramide	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	3541	11170	D004206
Verapamil	vindesine	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11204	11170	11204
Verapamil	vindesine	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11204	11170	11204
Verapamil	vindesine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11204	11170	11204
Verapamil	vindesine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11204	11170	11204
Verapamil	vindesine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11204	11170	11204
Verapamil	vindesine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11204	11170	11204
Verapamil	vindesine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11204	11170	11204
Verapamil	vindesine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11204	11170	11204
Verapamil	p450	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  		11170	none	11170	none
Verapamil	p450	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  		11170	none	11170	none
Verapamil	p450	2	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	none	11170	none
Verapamil	p450	2	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	none	11170	none
Verapamil	Telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	Telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	Telithromycin	2	3	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	Telithromycin	2	3	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	Telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	274786	11170	274786
Verapamil	Telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	274786	11170	274786
Verapamil	Telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	274786	11170	274786
Verapamil	Telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	274786	11170	274786
Verapamil	Telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	Telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	Telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	Telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	Telithromycin	31	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	274786	11170	274786
Verapamil	Telithromycin	31	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	274786	11170	274786
Verapamil	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	274786	11170	274786
Verapamil	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	274786	11170	274786
Verapamil	verapamil	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  		11170	11170
Verapamil	verapamil	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	11170
Verapamil	verapamil	2	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	11170
Verapamil	verapamil	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	11170
Verapamil	verapamil	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	11170
Verapamil	verapamil	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	11170
Verapamil	verapamil	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	11170
Verapamil	verapamil	4	5	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	11170
Verapamil	verapamil	4	6	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	11170
Verapamil	verapamil	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	11170
Verapamil	verapamil	5	5	false	none	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	11170
Verapamil	verapamil	5	6	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	11170
Verapamil	verapamil	5	7	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	11170
Verapamil	verapamil	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	11170
Verapamil	verapamil	6	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	11170
Verapamil	verapamil	6	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	11170
Verapamil	verapamil	6	7	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	11170
Verapamil	verapamil	6	8	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	11170
Verapamil	verapamil	7	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	11170
Verapamil	verapamil	7	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	11170
Verapamil	verapamil	7	7	false	none	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		11170	11170
Verapamil	verapamil	7	8	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	11170
Verapamil	verapamil	8	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	11170
Verapamil	verapamil	8	7	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	11170
Verapamil	verapamil	8	8	true	positive	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		11170	11170
Verapamil	verapamil	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	11170
Verapamil	verapamil	10	8	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	11170
Verapamil	verapamil	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	11170
Verapamil	verapamil	10	11	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	11170
Verapamil	verapamil	10	12	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	11170
Verapamil	verapamil	11	10	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	11170
Verapamil	verapamil	11	11	true	positive	This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	11170
Verapamil	verapamil	11	12	false	none	This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	11170
Verapamil	verapamil	11	13	false	none	This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied.  		11170	11170
Verapamil	verapamil	12	10	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	11170
Verapamil	verapamil	12	11	false	none	This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	11170
Verapamil	verapamil	12	12	false	none	7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	11170
Verapamil	verapamil	12	13	false	none	7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied.  		11170	11170
Verapamil	verapamil	13	11	false	none	This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied.  		11170	11170
Verapamil	verapamil	13	12	false	none	7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied.  		11170	11170
Verapamil	verapamil	13	13	false	none	The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied.  		11170	11170
Verapamil	verapamil	17	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  		11170	11170
Verapamil	verapamil	17	19	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	11170
Verapamil	verapamil	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	11170
Verapamil	verapamil	19	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	11170
Verapamil	verapamil	19	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  		11170	11170
Verapamil	verapamil	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	11170
Verapamil	verapamil	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	11170
Verapamil	verapamil	18	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	11170
Verapamil	verapamil	18	19	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	11170
Verapamil	verapamil	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	11170
Verapamil	verapamil	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	11170
Verapamil	verapamil	20	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	11170
Verapamil	verapamil	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	11170
Verapamil	verapamil	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	11170
Verapamil	verapamil	20	22	true	positive	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	11170
Verapamil	verapamil	23	23	false	none	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	11170
Verapamil	verapamil	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	11170
Verapamil	verapamil	23	24	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	11170
Verapamil	verapamil	22	20	true	positive	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	11170
Verapamil	verapamil	22	23	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	11170
Verapamil	verapamil	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	11170
Verapamil	verapamil	22	24	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	11170
Verapamil	verapamil	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	11170
Verapamil	verapamil	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	11170
Verapamil	verapamil	24	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	11170
Verapamil	verapamil	24	26	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	11170
Verapamil	verapamil	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	11170
Verapamil	verapamil	27	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	11170
Verapamil	verapamil	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	11170
Verapamil	verapamil	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	11170
Verapamil	verapamil	26	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	11170
Verapamil	verapamil	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	11170
Verapamil	verapamil	26	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		11170	11170
Verapamil	verapamil	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	11170
Verapamil	verapamil	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	11170
Verapamil	verapamil	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	11170
Verapamil	verapamil	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	11170
Verapamil	verapamil	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	11170
Verapamil	verapamil	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	11170
Verapamil	verapamil	28	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	11170
Verapamil	verapamil	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	11170
Verapamil	verapamil	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	11170
Verapamil	verapamil	31	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	11170
Verapamil	verapamil	31	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	11170
Verapamil	verapamil	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11170
Verapamil	verapamil	31	33	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11170
Verapamil	verapamil	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11170
Verapamil	verapamil	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	11170
Verapamil	verapamil	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11170
Verapamil	verapamil	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11170
Verapamil	verapamil	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	11170
Verapamil	verapamil	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	11170
Verapamil	verapamil	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	11170
Verapamil	verapamil	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	11170
Verapamil	verapamil	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	11170
Verapamil	verapamil	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	11170
Verapamil	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11170
Verapamil	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11170
Verapamil	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11170
Verapamil	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11170
Verapamil	verapamil	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11170
Verapamil	verapamil	33	34	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11170
Verapamil	verapamil	33	35	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	11170
Verapamil	verapamil	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11170
Verapamil	verapamil	33	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11170
Verapamil	verapamil	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		11170	11170
Verapamil	verapamil	38	39	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	11170
Verapamil	verapamil	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	11170
Verapamil	verapamil	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	11170
Verapamil	verapamil	38	40	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	11170
Verapamil	verapamil	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	11170
Verapamil	verapamil	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	11170
Verapamil	verapamil	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	11170
Verapamil	verapamil	39	40	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	11170
Verapamil	verapamil	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	11170
Verapamil	verapamil	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	11170
Verapamil	verapamil	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	11170
Verapamil	verapamil	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	11170
Verapamil	verapamil	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	11170
Verapamil	verapamil	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	11170
Verapamil	verapamil	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	11170
Verapamil	verapamil	37	39	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	11170
Verapamil	verapamil	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	11170
Verapamil	verapamil	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	11170
Verapamil	verapamil	42	42	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  		11170	11170
Verapamil	verapamil	42	43	true	positive	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		11170	11170
Verapamil	verapamil	42	40	false	none	7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  Monitor patients receiving these combinations appropriately.  Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  		11170	11170
Verapamil	verapamil	42	44	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	11170
Verapamil	verapamil	43	42	true	positive	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		11170	11170
Verapamil	verapamil	43	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  		11170	11170
Verapamil	verapamil	43	44	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	11170
Verapamil	verapamil	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	11170
Verapamil	verapamil	40	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	11170
Verapamil	verapamil	40	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	11170
Verapamil	verapamil	40	42	false	none	7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  Monitor patients receiving these combinations appropriately.  Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  		11170	11170
Verapamil	verapamil	40	40	false	none	7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	11170
Verapamil	verapamil	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	11170
Verapamil	verapamil	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	11170
Verapamil	verapamil	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	11170
Verapamil	verapamil	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	11170
Verapamil	verapamil	47	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	11170
Verapamil	verapamil	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	11170
Verapamil	verapamil	47	45	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	11170
Verapamil	verapamil	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	11170
Verapamil	verapamil	44	42	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	11170
Verapamil	verapamil	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	11170
Verapamil	verapamil	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	11170
Verapamil	verapamil	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		11170	11170
Verapamil	verapamil	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	11170
Verapamil	verapamil	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	11170
Verapamil	verapamil	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		11170	11170
Verapamil	verapamil	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	11170
Verapamil	verapamil	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	11170
Verapamil	verapamil	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		11170	11170
Verapamil	verapamil	51	51	false	none	However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	11170
Verapamil	verapamil	51	50	false	none	7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	11170
Verapamil	verapamil	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	11170
Verapamil	verapamil	50	51	false	none	7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	11170
Verapamil	verapamil	50	50	false	none	7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	11170
Verapamil	verapamil	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	11170
Verapamil	verapamil	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	11170
Verapamil	verapamil	49	51	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	11170
Verapamil	verapamil	49	50	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	11170
Verapamil	verapamil	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	11170
Verapamil	verapamil	55	55	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		11170	11170
Verapamil	verapamil	55	54	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		11170	11170
Verapamil	verapamil	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	11170
Verapamil	verapamil	55	56	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		11170	11170
Verapamil	verapamil	54	55	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  		11170	11170
Verapamil	verapamil	54	54	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  		11170	11170
Verapamil	verapamil	54	56	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		11170	11170
Verapamil	verapamil	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	11170
Verapamil	verapamil	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	11170
Verapamil	verapamil	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	11170
Verapamil	verapamil	59	61	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	11170
Verapamil	verapamil	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	11170
Verapamil	verapamil	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	11170
Verapamil	verapamil	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	11170
Verapamil	verapamil	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	11170
Verapamil	verapamil	58	56	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	11170
Verapamil	verapamil	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	11170
Verapamil	verapamil	57	55	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	11170
Verapamil	verapamil	57	59	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	11170
Verapamil	verapamil	57	58	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	11170
Verapamil	verapamil	57	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	11170
Verapamil	verapamil	57	56	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	11170
Verapamil	verapamil	56	55	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		11170	11170
Verapamil	verapamil	56	54	false	none	When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression.  7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		11170	11170
Verapamil	verapamil	56	58	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	11170
Verapamil	verapamil	56	57	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	11170
Verapamil	verapamil	56	56	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  		11170	11170
Verapamil	verapamil	62	62	false	none	7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	11170
Verapamil	verapamil	62	61	true	negative	Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	11170
Verapamil	verapamil	62	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	11170
Verapamil	verapamil	61	59	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	11170
Verapamil	verapamil	61	62	true	negative	Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	11170
Verapamil	verapamil	61	61	true	negative	Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	11170
Verapamil	verapamil	61	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	11170
Verapamil	verapamil	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	11170
Verapamil	verapamil	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	11170
Verapamil	verapamil	60	62	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	11170
Verapamil	verapamil	60	61	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	11170
Verapamil	verapamil	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	11170
Verapamil	ritonavir	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	85762	11170	D019438
Verapamil	ritonavir	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	85762	11170	D019438
Verapamil	ritonavir	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	85762	11170	D019438
Verapamil	ritonavir	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	85762	11170	D019438
Verapamil	ritonavir	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	85762	11170	D019438
Verapamil	ritonavir	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	85762	11170	D019438
Verapamil	Cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
Verapamil	Cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
Verapamil	carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
Verapamil	carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
Verapamil	carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	carbamazepine	47	48	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
Verapamil	carbamazepine	47	48	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
Verapamil	carbamazepine	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	carbamazepine	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
Verapamil	carbamazepine	50	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	2002	11170	D002220
Verapamil	carbamazepine	50	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	2002	11170	D002220
Verapamil	carbamazepine	49	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
Verapamil	carbamazepine	49	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
Verapamil	carbamazepine	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
Verapamil	carbamazepine	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
Verapamil	digitalis	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
Verapamil	digitalis	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
Verapamil	digitalis	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
Verapamil	digitalis	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
Verapamil	digitalis	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
Verapamil	digitalis	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
Verapamil	digitalis	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
Verapamil	digitalis	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
Verapamil	digitalis	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	none	11170	none
Verapamil	digitalis	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	none	11170	none
Verapamil	digitalis	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
Verapamil	digitalis	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
Verapamil	digitalis	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
Verapamil	digitalis	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
Verapamil	digitalis	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	none	11170	none
Verapamil	digitalis	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	none	11170	none
Verapamil	rifampin	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
Verapamil	rifampin	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
Verapamil	rifampin	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
Verapamil	rifampin	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
Verapamil	rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	9384	11170	9384
Verapamil	rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	9384	11170	9384
Verapamil	rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	9384	11170	9384
Verapamil	rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	9384	11170	9384
Verapamil	rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	9384	11170	9384
Verapamil	rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	9384	11170	9384
Verapamil	rifampin	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	rifampin	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	rifampin	57	58	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	rifampin	57	58	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	rifampin	56	58	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	rifampin	56	58	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
Verapamil	rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	9384	11170	9384
Verapamil	rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	9384	11170	9384
Verapamil	ethanol	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	448	11170	D000431
Verapamil	ethanol	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	448	11170	D000431
Verapamil	ethanol	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	448	11170	D000431
Verapamil	ethanol	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	448	11170	D000431
Verapamil	ethanol	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	448	11170	D000431
Verapamil	ethanol	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	448	11170	D000431
Verapamil	ethanol	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	448	11170	D000431
Verapamil	ethanol	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	448	11170	D000431
Verapamil	Clonidine	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
Verapamil	Clonidine	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
Verapamil	Clonidine	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
Verapamil	Clonidine	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
Verapamil	Clonidine	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
Verapamil	Clonidine	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
Verapamil	Clonidine	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
Verapamil	Clonidine	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
Verapamil	Clonidine	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
Verapamil	Clonidine	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
Verapamil	Clonidine	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
Verapamil	Clonidine	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
Verapamil	Clonidine	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
Verapamil	Clonidine	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
Verapamil	Clonidine	31	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	2599	11170	D003000
Verapamil	Clonidine	31	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	2599	11170	D003000
Verapamil	Theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
Verapamil	Theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
Verapamil	Theophylline	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
Verapamil	Theophylline	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
Verapamil	Theophylline	57	59	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
Verapamil	Theophylline	57	59	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
Verapamil	Theophylline	61	59	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	10438	11170	D013806
Verapamil	Theophylline	61	59	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	10438	11170	D013806
Verapamil	Theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	10438	11170	D013806
Verapamil	Theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	10438	11170	D013806
Verapamil	telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	telithromycin	2	3	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	telithromycin	2	3	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	274786	11170	274786
Verapamil	telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	274786	11170	274786
Verapamil	telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	274786	11170	274786
Verapamil	telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	274786	11170	274786
Verapamil	telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
Verapamil	telithromycin	31	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	274786	11170	274786
Verapamil	telithromycin	31	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	274786	11170	274786
Verapamil	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	274786	11170	274786
Verapamil	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	274786	11170	274786
Verapamil	paclitaxel	31	33	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
Verapamil	paclitaxel	31	33	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
Verapamil	paclitaxel	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	56946	11170	56946
Verapamil	paclitaxel	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	56946	11170	56946
Verapamil	paclitaxel	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	56946	11170	56946
Verapamil	paclitaxel	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	56946	11170	56946
Verapamil	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
Verapamil	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
Verapamil	paclitaxel	33	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
Verapamil	paclitaxel	33	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
Verapamil	procarbazine	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8702	11170	8702
Verapamil	procarbazine	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8702	11170	8702
Verapamil	procarbazine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	8702	11170	8702
Verapamil	procarbazine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	8702	11170	8702
Verapamil	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8702	11170	8702
Verapamil	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8702	11170	8702
Verapamil	procarbazine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	8702	11170	8702
Verapamil	procarbazine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	8702	11170	8702
Verapamil	Quinidine	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
Verapamil	Quinidine	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
Verapamil	Quinidine	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
Verapamil	Quinidine	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
Verapamil	Quinidine	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
Verapamil	Quinidine	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
Verapamil	Quinidine	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
Verapamil	Quinidine	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
Verapamil	Quinidine	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
Verapamil	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
Verapamil	Quinidine	33	34	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
Verapamil	Quinidine	33	34	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
Verapamil	Quinidine	33	35	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
Verapamil	Quinidine	33	35	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
Verapamil	Quinidine	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	9068	11170	9068
Verapamil	Quinidine	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	9068	11170	9068
Verapamil	Quinidine	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	9068	11170	9068
Verapamil	Quinidine	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	9068	11170	9068
Verapamil	Quinidine	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
Verapamil	Quinidine	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
Verapamil	Quinidine	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
Verapamil	Quinidine	40	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	9068	11170	9068
Verapamil	Quinidine	40	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	9068	11170	9068
Verapamil	cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
Verapamil	cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
Verapamil	cyclosporine	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	3008	11170	D016572
Verapamil	cyclosporine	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	3008	11170	D016572
Verapamil	cyclosporine	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	3008	11170	D016572
Verapamil	cyclosporine	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	3008	11170	D016572
Verapamil	cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
Verapamil	cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
Verapamil	norverapamil	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	11	10	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	none	11170	C016904
Verapamil	norverapamil	11	10	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	none	11170	C016904
Verapamil	norverapamil	12	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	none	11170	C016904
Verapamil	norverapamil	12	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	none	11170	C016904
Verapamil	Phenobarbital	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	57	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	57	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	56	57	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
Verapamil	Phenobarbital	56	57	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
Verapamil	doxorubicin	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	3639	11170	3639
Verapamil	doxorubicin	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	3639	11170	3639
Verapamil	doxorubicin	31	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	3639	11170	3639
Verapamil	doxorubicin	31	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	3639	11170	3639
Verapamil	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	3639	11170	3639
Verapamil	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	3639	11170	3639
Verapamil	doxorubicin	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	3639	11170	3639
Verapamil	doxorubicin	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	3639	11170	3639
Verapamil	erythromycin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	4053	11170	D004917
Verapamil	erythromycin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	4053	11170	D004917
Verapamil	erythromycin	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	4053	11170	D004917
Verapamil	erythromycin	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	4053	11170	D004917
Verapamil	erythromycin	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	4053	11170	D004917
Verapamil	erythromycin	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	4053	11170	D004917
Verapamil	Cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
Verapamil	Cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
Verapamil	Cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
Verapamil	Cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
Verapamil	Cimetidine	62	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	2541	11170	2541
Verapamil	Cimetidine	62	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	2541	11170	2541
Verapamil	Cimetidine	61	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	2541	11170	2541
Verapamil	Cimetidine	61	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	2541	11170	2541
Verapamil	Cimetidine	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
Verapamil	Cimetidine	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
Verapamil	metoprolol	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	6918	11170	D008790
Verapamil	metoprolol	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	6918	11170	D008790
Verapamil	metoprolol	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	6918	11170	D008790
Verapamil	metoprolol	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	6918	11170	D008790
Verapamil	metoprolol	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	6918	11170	D008790
Verapamil	metoprolol	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	6918	11170	D008790
Verapamil	metoprolol	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	6918	11170	D008790
Verapamil	metoprolol	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	6918	11170	D008790
Verapamil	prednisone	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8640	11170	D011241
Verapamil	prednisone	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8640	11170	D011241
Verapamil	prednisone	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	8640	11170	D011241
Verapamil	prednisone	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	8640	11170	D011241
Verapamil	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8640	11170	D011241
Verapamil	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8640	11170	D011241
Verapamil	prednisone	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	8640	11170	D011241
Verapamil	prednisone	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	8640	11170	D011241
Verapamil	oncovin	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11202	11170	D014750
Verapamil	oncovin	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11202	11170	D014750
Verapamil	oncovin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11202	11170	D014750
Verapamil	oncovin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11202	11170	D014750
Verapamil	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11202	11170	D014750
Verapamil	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11202	11170	D014750
Verapamil	oncovin	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11202	11170	D014750
Verapamil	oncovin	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11202	11170	D014750
Carbamazepine	flecainide	48	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		2002	4441	D002220	4441
Carbamazepine	flecainide	48	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		2002	4441	D002220	4441
Carbamazepine	flecainide	47	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	4441	D002220	4441
Carbamazepine	flecainide	47	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	4441	D002220	4441
Carbamazepine	flecainide	47	45	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	4441	D002220	4441
Carbamazepine	flecainide	47	45	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	4441	D002220	4441
Carbamazepine	verapamil	48	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		2002	11170	D002220	11170
Carbamazepine	verapamil	48	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		2002	11170	D002220	11170
Carbamazepine	verapamil	48	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		2002	11170	D002220	11170
Carbamazepine	verapamil	48	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		2002	11170	D002220	11170
Carbamazepine	verapamil	48	50	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		2002	11170	D002220	11170
Carbamazepine	verapamil	48	50	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		2002	11170	D002220	11170
Carbamazepine	verapamil	48	49	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	11170	D002220	11170
Carbamazepine	verapamil	48	49	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	11170	D002220	11170
Carbamazepine	verapamil	47	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	11170	D002220	11170
Carbamazepine	verapamil	47	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	11170	D002220	11170
Carbamazepine	verapamil	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	11170	D002220	11170
Carbamazepine	verapamil	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	11170	D002220	11170
Carbamazepine	verapamil	47	45	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	11170	D002220	11170
Carbamazepine	verapamil	47	45	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		2002	11170	D002220	11170
Carbamazepine	verapamil	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	11170	D002220	11170
Carbamazepine	verapamil	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	11170	D002220	11170
Carbamazepine	Cyclosporine	48	49	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
Carbamazepine	Cyclosporine	48	49	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
Carbamazepine	Cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
Carbamazepine	Cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
Carbamazepine	carbamazepine	48	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		D002220	D002220
Carbamazepine	carbamazepine	48	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		D002220	D002220
Carbamazepine	carbamazepine	47	48	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		D002220	D002220
Carbamazepine	carbamazepine	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		D002220	D002220
Carbamazepine	cyclosporine	48	49	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
Carbamazepine	cyclosporine	48	49	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
Carbamazepine	cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
Carbamazepine	cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
flecainide	disopyramide	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	3541	4441	D004206
flecainide	disopyramide	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	3541	4441	D004206
flecainide	disopyramide	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	3541	4441	D004206
flecainide	disopyramide	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	3541	4441	D004206
flecainide	verapamil	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
flecainide	verapamil	46	46	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
flecainide	verapamil	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
flecainide	verapamil	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
flecainide	verapamil	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
flecainide	verapamil	46	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
flecainide	verapamil	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
flecainide	verapamil	46	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
flecainide	verapamil	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
flecainide	verapamil	45	43	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
flecainide	verapamil	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
flecainide	verapamil	45	46	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		4441	11170	4441	11170
flecainide	verapamil	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
flecainide	verapamil	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	11170	4441	11170
flecainide	verapamil	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
flecainide	verapamil	45	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
flecainide	verapamil	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
flecainide	verapamil	45	45	true	positive	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		4441	11170	4441	11170
flecainide	carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		4441	2002	4441	D002220
flecainide	carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		4441	2002	4441	D002220
flecainide	carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
flecainide	carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
flecainide	carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
flecainide	carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		4441	2002	4441	D002220
grapefruit	Rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	9384	none	9384
grapefruit	Rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	9384	none	9384
grapefruit	Rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	9384	none	9384
grapefruit	Rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	9384	none	9384
grapefruit	Telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	274786	none	274786
grapefruit	Telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	274786	none	274786
grapefruit	verapamil	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	11170	none	11170
grapefruit	verapamil	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	11170	none	11170
grapefruit	verapamil	5	5	false	none	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	11170	none	11170
grapefruit	verapamil	5	5	false	none	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	11170	none	11170
grapefruit	verapamil	5	6	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	11170	none	11170
grapefruit	verapamil	5	6	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	11170	none	11170
grapefruit	verapamil	5	7	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	5	7	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	11170	none	11170
grapefruit	verapamil	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	11170	none	11170
grapefruit	verapamil	6	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	11170	none	11170
grapefruit	verapamil	6	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	11170	none	11170
grapefruit	verapamil	6	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	11170	none	11170
grapefruit	verapamil	6	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	11170	none	11170
grapefruit	verapamil	6	7	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	6	7	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	6	8	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		none	11170	none	11170
grapefruit	verapamil	6	8	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		none	11170	none	11170
grapefruit	verapamil	7	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	7	5	true	positive	7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	7	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	7	6	true	positive	Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	7	7	false	none	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	7	7	false	none	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  		none	11170	none	11170
grapefruit	verapamil	7	8	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		none	11170	none	11170
grapefruit	verapamil	7	8	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  		none	11170	none	11170
grapefruit	verapamil	9	7	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  		none	11170	none	11170
grapefruit	verapamil	9	7	true	positive	Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control.  Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  		none	11170	none	11170
grapefruit	verapamil	9	8	true	positive	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  		none	11170	none	11170
grapefruit	verapamil	9	8	true	positive	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  		none	11170	none	11170
grapefruit	verapamil	9	10	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		none	11170	none	11170
grapefruit	verapamil	9	10	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		none	11170	none	11170
grapefruit	verapamil	9	11	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		none	11170	none	11170
grapefruit	verapamil	9	11	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		none	11170	none	11170
grapefruit	verapamil	10	8	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		none	11170	none	11170
grapefruit	verapamil	10	8	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		none	11170	none	11170
grapefruit	verapamil	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		none	11170	none	11170
grapefruit	verapamil	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		none	11170	none	11170
grapefruit	verapamil	10	11	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		none	11170	none	11170
grapefruit	verapamil	10	11	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		none	11170	none	11170
grapefruit	verapamil	10	12	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		none	11170	none	11170
grapefruit	verapamil	10	12	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		none	11170	none	11170
grapefruit	rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	9384	none	9384
grapefruit	rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	9384	none	9384
grapefruit	rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	9384	none	9384
grapefruit	rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		none	9384	none	9384
grapefruit	telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	274786	none	274786
grapefruit	telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		none	274786	none	274786
grapefruit	norverapamil	9	10	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		none	none	none	C016904
grapefruit	norverapamil	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		none	none	none	C016904
Rifampin	Telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	274786	9384	274786
Rifampin	Telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	274786	9384	274786
Rifampin	verapamil	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	11170	9384	11170
Rifampin	verapamil	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	11170	9384	11170
Rifampin	verapamil	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	11170	9384	11170
Rifampin	verapamil	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	11170	9384	11170
Rifampin	verapamil	4	5	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		9384	11170	9384	11170
Rifampin	verapamil	4	5	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		9384	11170	9384	11170
Rifampin	verapamil	4	6	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		9384	11170	9384	11170
Rifampin	verapamil	4	6	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		9384	11170	9384	11170
Rifampin	verapamil	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		9384	11170	9384	11170
Rifampin	verapamil	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		9384	11170	9384	11170
Rifampin	verapamil	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	11170	9384	11170
Rifampin	verapamil	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	11170	9384	11170
Rifampin	verapamil	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	11170	9384	11170
Rifampin	verapamil	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	11170	9384	11170
Rifampin	verapamil	58	56	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	11170	9384	11170
Rifampin	verapamil	58	56	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	11170	9384	11170
Rifampin	verapamil	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		9384	11170	9384	11170
Rifampin	verapamil	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		9384	11170	9384	11170
Rifampin	ritonavir	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	85762	9384	D019438
Rifampin	ritonavir	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	85762	9384	D019438
Rifampin	rifampin	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	9384
Rifampin	rifampin	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	9384
Rifampin	Theophylline	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		9384	10438	9384	D013806
Rifampin	Theophylline	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		9384	10438	9384	D013806
Rifampin	telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	274786	9384	274786
Rifampin	telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	274786	9384	274786
Rifampin	Phenobarbital	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	8134	9384	D010634
Rifampin	Phenobarbital	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	8134	9384	D010634
Rifampin	erythromycin	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	4053	9384	D004917
Rifampin	erythromycin	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	4053	9384	D004917
Rifampin	Cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		9384	2541	9384	2541
Rifampin	Cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		9384	2541	9384	2541
digoxin	atenolol	21	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		3407	1202	3407	D001262
digoxin	atenolol	21	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		3407	1202	3407	D001262
digoxin	atenolol	20	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	1202	3407	D001262
digoxin	atenolol	20	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	1202	3407	D001262
digoxin	verapamil	21	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		3407	11170	3407	11170
digoxin	verapamil	21	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		3407	11170	3407	11170
digoxin	verapamil	21	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		3407	11170	3407	11170
digoxin	verapamil	21	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		3407	11170	3407	11170
digoxin	verapamil	21	23	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	11170	3407	11170
digoxin	verapamil	21	23	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	11170	3407	11170
digoxin	verapamil	21	22	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	11170	3407	11170
digoxin	verapamil	21	22	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	11170	3407	11170
digoxin	verapamil	20	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	11170	3407	11170
digoxin	verapamil	20	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	11170	3407	11170
digoxin	verapamil	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	11170	3407	11170
digoxin	verapamil	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	11170	3407	11170
digoxin	verapamil	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	11170	3407	11170
digoxin	verapamil	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	11170	3407	11170
digoxin	verapamil	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	11170	3407	11170
digoxin	verapamil	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	11170	3407	11170
digoxin	verapamil	23	23	false	none	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	11170	3407	11170
digoxin	verapamil	23	23	false	none	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	11170	3407	11170
digoxin	verapamil	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	11170	3407	11170
digoxin	verapamil	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	11170	3407	11170
digoxin	verapamil	23	24	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3407	11170	3407	11170
digoxin	verapamil	23	24	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3407	11170	3407	11170
digoxin	verapamil	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	11170	3407	11170
digoxin	verapamil	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	11170	3407	11170
digoxin	verapamil	22	23	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	11170	3407	11170
digoxin	verapamil	22	23	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	11170	3407	11170
digoxin	verapamil	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	11170	3407	11170
digoxin	verapamil	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	11170	3407	11170
digoxin	verapamil	22	24	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3407	11170	3407	11170
digoxin	verapamil	22	24	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		3407	11170	3407	11170
digoxin	verapamil	25	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		3407	11170	3407	11170
digoxin	verapamil	25	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		3407	11170	3407	11170
digoxin	verapamil	25	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		3407	11170	3407	11170
digoxin	verapamil	25	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  		3407	11170	3407	11170
digoxin	verapamil	25	27	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		3407	11170	3407	11170
digoxin	verapamil	25	27	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		3407	11170	3407	11170
digoxin	verapamil	25	26	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3407	11170	3407	11170
digoxin	verapamil	25	26	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3407	11170	3407	11170
digoxin	verapamil	26	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3407	11170	3407	11170
digoxin	verapamil	26	24	true	positive	Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3407	11170	3407	11170
digoxin	verapamil	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		3407	11170	3407	11170
digoxin	verapamil	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		3407	11170	3407	11170
digoxin	verapamil	26	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3407	11170	3407	11170
digoxin	verapamil	26	26	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  		3407	11170	3407	11170
digoxin	verapamil	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		3407	11170	3407	11170
digoxin	verapamil	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		3407	11170	3407	11170
digoxin	digitalis	21	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		3407	none	3407	none
digoxin	digitalis	21	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  		3407	none	3407	none
digoxin	digitalis	21	22	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	none	3407	none
digoxin	digitalis	21	22	true	positive	Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	none	3407	none
digoxin	digitalis	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	none	3407	none
digoxin	digitalis	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	none	3407	none
digoxin	digitalis	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	none	3407	none
digoxin	digitalis	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	none	3407	none
digoxin	digitalis	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	none	3407	none
digoxin	digitalis	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		3407	none	3407	none
digoxin	digitalis	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	none	3407	none
digoxin	digitalis	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	none	3407	none
digoxin	digitalis	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	none	3407	none
digoxin	digitalis	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		3407	none	3407	none
digoxin	ethanol	25	27	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		3407	448	3407	D000431
digoxin	ethanol	25	27	false	none	If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.  In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		3407	448	3407	D000431
digoxin	ethanol	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		3407	448	3407	D000431
digoxin	ethanol	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		3407	448	3407	D000431
digoxin	Clonidine	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		3407	2599	3407	D003000
digoxin	Clonidine	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		3407	2599	3407	D003000
digoxin	metoprolol	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	6918	3407	D008790
digoxin	metoprolol	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		3407	6918	3407	D008790
atenolol	verapamil	19	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		1202	11170	D001262	11170
atenolol	verapamil	19	17	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		1202	11170	D001262	11170
atenolol	verapamil	19	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  		1202	11170	D001262	11170
atenolol	verapamil	19	19	false	none	A variable effect has been seen when verapamil and atenolol were given together.  		1202	11170	D001262	11170
atenolol	verapamil	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		1202	11170	D001262	11170
atenolol	verapamil	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		1202	11170	D001262	11170
atenolol	verapamil	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		1202	11170	D001262	11170
atenolol	verapamil	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		1202	11170	D001262	11170
atenolol	digitalis	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		1202	none	D001262	none
atenolol	digitalis	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		1202	none	D001262	none
atenolol	metoprolol	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		1202	6918	D001262	D008790
atenolol	metoprolol	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		1202	6918	D001262	D008790
aspirin	verapamil	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
aspirin	verapamil	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
aspirin	verapamil	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
aspirin	verapamil	39	39	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
aspirin	verapamil	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
aspirin	verapamil	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	11170	1191	11170
aspirin	verapamil	39	40	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		1191	11170	1191	11170
aspirin	verapamil	39	40	false	none	7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		1191	11170	1191	11170
aspirin	Quinidine	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	9068	1191	9068
aspirin	Quinidine	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	9068	1191	9068
aspirin	Quinidine	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	9068	1191	9068
aspirin	Quinidine	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		1191	9068	1191	9068
disopyramide	verapamil	44	42	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
disopyramide	verapamil	44	42	false	none	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
disopyramide	verapamil	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
disopyramide	verapamil	44	43	false	none	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
disopyramide	verapamil	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		3541	11170	D004206	11170
disopyramide	verapamil	44	46	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  		3541	11170	D004206	11170
disopyramide	verapamil	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
disopyramide	verapamil	44	44	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  		3541	11170	D004206	11170
disopyramide	verapamil	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		3541	11170	D004206	11170
disopyramide	verapamil	44	45	false	none	7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  		3541	11170	D004206	11170
vindesine	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	274786	11204	274786
vindesine	Telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	274786	11204	274786
vindesine	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	11170	11204	11170
vindesine	verapamil	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	11170	11204	11170
vindesine	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11204	11170	11204	11170
vindesine	verapamil	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11204	11170	11204	11170
vindesine	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	11170	11204	11170
vindesine	verapamil	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	11170	11204	11170
vindesine	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11204	11170	11204	11170
vindesine	verapamil	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11204	11170	11204	11170
vindesine	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	274786	11204	274786
vindesine	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	274786	11204	274786
vindesine	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11204	56946	11204	56946
vindesine	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11204	56946	11204	56946
vindesine	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	8702	11204	8702
vindesine	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	8702	11204	8702
vindesine	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11204	9068	11204	9068
vindesine	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11204	9068	11204	9068
vindesine	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	3639	11204	3639
vindesine	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	3639	11204	3639
vindesine	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	8640	11204	D011241
vindesine	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	8640	11204	D011241
vindesine	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	11202	11204	D014750
vindesine	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11204	11202	11204	D014750
p450	Telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		none	274786	none	274786
p450	Telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		none	274786	none	274786
p450	verapamil	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  		none	11170	none	11170
p450	verapamil	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  		none	11170	none	11170
p450	verapamil	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		none	11170	none	11170
p450	verapamil	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		none	11170	none	11170
p450	ritonavir	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		none	85762	none	D019438
p450	ritonavir	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		none	85762	none	D019438
p450	telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		none	274786	none	274786
p450	telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		none	274786	none	274786
p450	erythromycin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		none	4053	none	D004917
p450	erythromycin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		none	4053	none	D004917
Telithromycin	verapamil	3	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	11170	274786	11170
Telithromycin	verapamil	3	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	11170	274786	11170
Telithromycin	verapamil	3	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	11170	274786	11170
Telithromycin	verapamil	3	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	11170	274786	11170
Telithromycin	verapamil	3	4	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		274786	11170	274786	11170
Telithromycin	verapamil	3	4	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		274786	11170	274786	11170
Telithromycin	verapamil	3	5	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		274786	11170	274786	11170
Telithromycin	verapamil	3	5	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		274786	11170	274786	11170
Telithromycin	verapamil	30	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	11170	274786	11170
Telithromycin	verapamil	30	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	11170	274786	11170
Telithromycin	verapamil	30	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	11170	274786	11170
Telithromycin	verapamil	30	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	11170	274786	11170
Telithromycin	verapamil	30	31	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		274786	11170	274786	11170
Telithromycin	verapamil	30	31	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		274786	11170	274786	11170
Telithromycin	verapamil	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	11170	274786	11170
Telithromycin	verapamil	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	11170	274786	11170
Telithromycin	ritonavir	3	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	85762	274786	D019438
Telithromycin	ritonavir	3	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	85762	274786	D019438
Telithromycin	rifampin	3	4	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		274786	9384	274786	9384
Telithromycin	rifampin	3	4	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		274786	9384	274786	9384
Telithromycin	Clonidine	30	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	2599	274786	D003000
Telithromycin	Clonidine	30	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	2599	274786	D003000
Telithromycin	Clonidine	30	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	2599	274786	D003000
Telithromycin	Clonidine	30	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	2599	274786	D003000
Telithromycin	telithromycin	3	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	274786
Telithromycin	telithromycin	30	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		274786	274786
Telithromycin	procarbazine	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	8702	274786	8702
Telithromycin	procarbazine	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	8702	274786	8702
Telithromycin	doxorubicin	30	31	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		274786	3639	274786	3639
Telithromycin	doxorubicin	30	31	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		274786	3639	274786	3639
Telithromycin	erythromycin	3	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	4053	274786	D004917
Telithromycin	erythromycin	3	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	4053	274786	D004917
Telithromycin	prednisone	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	8640	274786	D011241
Telithromycin	prednisone	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	8640	274786	D011241
Telithromycin	oncovin	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	11202	274786	D014750
Telithromycin	oncovin	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	11202	274786	D014750
verapamil	ritonavir	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	85762	11170	D019438
verapamil	ritonavir	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	85762	11170	D019438
verapamil	ritonavir	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	85762	11170	D019438
verapamil	ritonavir	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	85762	11170	D019438
verapamil	ritonavir	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	85762	11170	D019438
verapamil	ritonavir	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	85762	11170	D019438
verapamil	Cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
verapamil	Cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
verapamil	Cyclosporine	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	3008	11170	D016572
verapamil	Cyclosporine	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	3008	11170	D016572
verapamil	Cyclosporine	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	3008	11170	D016572
verapamil	Cyclosporine	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	3008	11170	D016572
verapamil	Cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
verapamil	Cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
verapamil	carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
verapamil	carbamazepine	46	48	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
verapamil	carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
verapamil	carbamazepine	46	47	false	none	Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
verapamil	carbamazepine	47	48	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
verapamil	carbamazepine	47	48	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  		11170	2002	11170	D002220
verapamil	carbamazepine	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
verapamil	carbamazepine	47	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
verapamil	carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
verapamil	carbamazepine	45	47	false	none	7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.  Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.  7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  		11170	2002	11170	D002220
verapamil	carbamazepine	50	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	2002	11170	D002220
verapamil	carbamazepine	50	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	2002	11170	D002220
verapamil	carbamazepine	49	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
verapamil	carbamazepine	49	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
verapamil	carbamazepine	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
verapamil	carbamazepine	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	2002	11170	D002220
verapamil	digitalis	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
verapamil	digitalis	19	20	false	none	A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
verapamil	digitalis	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
verapamil	digitalis	18	20	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
verapamil	digitalis	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
verapamil	digitalis	20	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	none	11170	none
verapamil	digitalis	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
verapamil	digitalis	20	22	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
verapamil	digitalis	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	none	11170	none
verapamil	digitalis	23	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  		11170	none	11170	none
verapamil	digitalis	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
verapamil	digitalis	22	20	false	none	7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  Monitor digoxin level periodically during therapy.  Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
verapamil	digitalis	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
verapamil	digitalis	22	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  		11170	none	11170	none
verapamil	digitalis	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	none	11170	none
verapamil	digitalis	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.  		11170	none	11170	none
verapamil	rifampin	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
verapamil	rifampin	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
verapamil	rifampin	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
verapamil	rifampin	4	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	9384	11170	9384
verapamil	rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	9384	11170	9384
verapamil	rifampin	5	4	false	none	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	9384	11170	9384
verapamil	rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	9384	11170	9384
verapamil	rifampin	6	4	true	positive	Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.  		11170	9384	11170	9384
verapamil	rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	9384	11170	9384
verapamil	rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	9384	11170	9384
verapamil	rifampin	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
verapamil	rifampin	58	58	false	none	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
verapamil	rifampin	57	58	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
verapamil	rifampin	57	58	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
verapamil	rifampin	56	58	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
verapamil	rifampin	56	58	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	9384	11170	9384
verapamil	rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	9384	11170	9384
verapamil	rifampin	60	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	9384	11170	9384
verapamil	ethanol	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	448	11170	D000431
verapamil	ethanol	27	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	448	11170	D000431
verapamil	ethanol	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	448	11170	D000431
verapamil	ethanol	26	27	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  		11170	448	11170	D000431
verapamil	ethanol	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	448	11170	D000431
verapamil	ethanol	29	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	448	11170	D000431
verapamil	ethanol	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	448	11170	D000431
verapamil	ethanol	28	27	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	448	11170	D000431
verapamil	Clonidine	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
verapamil	Clonidine	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
verapamil	Clonidine	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
verapamil	Clonidine	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
verapamil	Clonidine	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
verapamil	Clonidine	26	28	false	none	In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.  7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
verapamil	Clonidine	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
verapamil	Clonidine	29	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
verapamil	Clonidine	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
verapamil	Clonidine	29	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
verapamil	Clonidine	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
verapamil	Clonidine	28	29	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		11170	2599	11170	D003000
verapamil	Clonidine	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
verapamil	Clonidine	28	28	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		11170	2599	11170	D003000
verapamil	Clonidine	31	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	2599	11170	D003000
verapamil	Clonidine	31	29	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	2599	11170	D003000
verapamil	Theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
verapamil	Theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
verapamil	Theophylline	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
verapamil	Theophylline	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
verapamil	Theophylline	57	59	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
verapamil	Theophylline	57	59	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	10438	11170	D013806
verapamil	Theophylline	61	59	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	10438	11170	D013806
verapamil	Theophylline	61	59	true	negative	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	10438	11170	D013806
verapamil	Theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	10438	11170	D013806
verapamil	Theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	10438	11170	D013806
verapamil	telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
verapamil	telithromycin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
verapamil	telithromycin	2	3	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
verapamil	telithromycin	2	3	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
verapamil	telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	274786	11170	274786
verapamil	telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	274786	11170	274786
verapamil	telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	274786	11170	274786
verapamil	telithromycin	5	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  7.2 Grapefruit Juice    Grapefruit juice may significantly increase concentrations of verapamil.  		11170	274786	11170	274786
verapamil	telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
verapamil	telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
verapamil	telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
verapamil	telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		11170	274786	11170	274786
verapamil	telithromycin	31	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	274786	11170	274786
verapamil	telithromycin	31	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	274786	11170	274786
verapamil	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	274786	11170	274786
verapamil	telithromycin	32	30	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	274786	11170	274786
verapamil	paclitaxel	31	33	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
verapamil	paclitaxel	31	33	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
verapamil	paclitaxel	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	56946	11170	56946
verapamil	paclitaxel	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	56946	11170	56946
verapamil	paclitaxel	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	56946	11170	56946
verapamil	paclitaxel	35	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	56946	11170	56946
verapamil	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
verapamil	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
verapamil	paclitaxel	33	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
verapamil	paclitaxel	33	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	56946	11170	56946
verapamil	procarbazine	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8702	11170	8702
verapamil	procarbazine	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8702	11170	8702
verapamil	procarbazine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	8702	11170	8702
verapamil	procarbazine	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	8702	11170	8702
verapamil	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8702	11170	8702
verapamil	procarbazine	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8702	11170	8702
verapamil	procarbazine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	8702	11170	8702
verapamil	procarbazine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	8702	11170	8702
verapamil	Quinidine	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
verapamil	Quinidine	34	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
verapamil	Quinidine	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
verapamil	Quinidine	34	35	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
verapamil	Quinidine	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	34	36	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
verapamil	Quinidine	35	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
verapamil	Quinidine	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
verapamil	Quinidine	35	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
verapamil	Quinidine	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	35	36	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	35	37	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
verapamil	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
verapamil	Quinidine	33	34	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
verapamil	Quinidine	33	34	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	9068	11170	9068
verapamil	Quinidine	33	35	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
verapamil	Quinidine	33	35	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		11170	9068	11170	9068
verapamil	Quinidine	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	38	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	38	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	38	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	9068	11170	9068
verapamil	Quinidine	39	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	9068	11170	9068
verapamil	Quinidine	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	9068	11170	9068
verapamil	Quinidine	39	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  		11170	9068	11170	9068
verapamil	Quinidine	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	36	34	false	none	7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	36	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	36	38	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	36	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  		11170	9068	11170	9068
verapamil	Quinidine	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	36	37	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	37	35	false	none	Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	37	38	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  There has been a report of increased quinidine levels during verapamil therapy.  		11170	9068	11170	9068
verapamil	Quinidine	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	37	36	false	none	The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients.  Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	37	37	false	none	Verapamil significantly counteracted the effects of quinidine on AV conduction.  		11170	9068	11170	9068
verapamil	Quinidine	40	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	9068	11170	9068
verapamil	Quinidine	40	38	false	none	There has been a report of increased quinidine levels during verapamil therapy.  7.10 Aspirin    In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.  7.11 Antihypertensive agents    Verapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure.  		11170	9068	11170	9068
verapamil	cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
verapamil	cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
verapamil	cyclosporine	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	3008	11170	D016572
verapamil	cyclosporine	51	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.  		11170	3008	11170	D016572
verapamil	cyclosporine	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	3008	11170	D016572
verapamil	cyclosporine	50	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  7.16 Lithium    Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.  		11170	3008	11170	D016572
verapamil	cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
verapamil	cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		11170	3008	11170	D016572
verapamil	norverapamil	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	10	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	11	10	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	none	11170	C016904
verapamil	norverapamil	11	10	true	negative	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  		11170	none	11170	C016904
verapamil	norverapamil	12	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	none	11170	C016904
verapamil	norverapamil	12	10	false	none	Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.  This increase in verapamil plasma concentration is not expected to have any clinical consequences.  7.3 Beta-Blockers    Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility.  		11170	none	11170	C016904
verapamil	Phenobarbital	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
verapamil	Phenobarbital	55	57	false	none	7.18 Neuromuscular Blocking Agents    Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing).  It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
verapamil	Phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	8134	11170	D010634
verapamil	Phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		11170	8134	11170	D010634
verapamil	Phenobarbital	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	8134	11170	D010634
verapamil	Phenobarbital	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		11170	8134	11170	D010634
verapamil	Phenobarbital	57	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
verapamil	Phenobarbital	57	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
verapamil	Phenobarbital	56	57	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
verapamil	Phenobarbital	56	57	false	none	It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.  7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  		11170	8134	11170	D010634
verapamil	doxorubicin	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	3639	11170	3639
verapamil	doxorubicin	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	3639	11170	3639
verapamil	doxorubicin	31	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	3639	11170	3639
verapamil	doxorubicin	31	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		11170	3639	11170	3639
verapamil	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	3639	11170	3639
verapamil	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	3639	11170	3639
verapamil	doxorubicin	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	3639	11170	3639
verapamil	doxorubicin	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	3639	11170	3639
verapamil	erythromycin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	4053	11170	D004917
verapamil	erythromycin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Inhibitors and Inducers    In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C.  Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	4053	11170	D004917
verapamil	erythromycin	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	4053	11170	D004917
verapamil	erythromycin	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		11170	4053	11170	D004917
verapamil	erythromycin	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	4053	11170	D004917
verapamil	erythromycin	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		11170	4053	11170	D004917
verapamil	Cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
verapamil	Cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
verapamil	Cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
verapamil	Cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
verapamil	Cimetidine	62	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	2541	11170	2541
verapamil	Cimetidine	62	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  7.23 Nitrates    Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions.  		11170	2541	11170	2541
verapamil	Cimetidine	61	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	2541	11170	2541
verapamil	Cimetidine	61	60	true	negative	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.  		11170	2541	11170	2541
verapamil	Cimetidine	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
verapamil	Cimetidine	60	60	false	none	7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		11170	2541	11170	2541
verapamil	metoprolol	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	6918	11170	D008790
verapamil	metoprolol	17	18	false	none	Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.  A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	6918	11170	D008790
verapamil	metoprolol	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	6918	11170	D008790
verapamil	metoprolol	19	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  		11170	6918	11170	D008790
verapamil	metoprolol	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	6918	11170	D008790
verapamil	metoprolol	18	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  		11170	6918	11170	D008790
verapamil	metoprolol	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	6918	11170	D008790
verapamil	metoprolol	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		11170	6918	11170	D008790
verapamil	prednisone	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8640	11170	D011241
verapamil	prednisone	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8640	11170	D011241
verapamil	prednisone	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	8640	11170	D011241
verapamil	prednisone	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	8640	11170	D011241
verapamil	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8640	11170	D011241
verapamil	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	8640	11170	D011241
verapamil	prednisone	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	8640	11170	D011241
verapamil	prednisone	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	8640	11170	D011241
verapamil	oncovin	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11202	11170	D014750
verapamil	oncovin	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11202	11170	D014750
verapamil	oncovin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11202	11170	D014750
verapamil	oncovin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		11170	11202	11170	D014750
verapamil	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11202	11170	D014750
verapamil	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		11170	11202	11170	D014750
verapamil	oncovin	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11202	11170	D014750
verapamil	oncovin	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		11170	11202	11170	D014750
ritonavir	rifampin	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		85762	9384	D019438	9384
ritonavir	rifampin	2	4	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		85762	9384	D019438	9384
ritonavir	telithromycin	2	3	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		85762	274786	D019438	274786
ritonavir	telithromycin	2	3	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		85762	274786	D019438	274786
ritonavir	erythromycin	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		85762	4053	D019438	D004917
ritonavir	erythromycin	2	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  		85762	4053	D019438	D004917
Cyclosporine	carbamazepine	49	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		3008	2002	D016572	D002220
Cyclosporine	carbamazepine	49	48	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		3008	2002	D016572	D002220
Cyclosporine	carbamazepine	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		3008	2002	D016572	D002220
Cyclosporine	carbamazepine	49	47	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		3008	2002	D016572	D002220
Cyclosporine	cyclosporine	49	49	false	none	7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		D016572	D016572
carbamazepine	cyclosporine	48	49	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
carbamazepine	cyclosporine	48	49	false	none	This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
carbamazepine	cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
carbamazepine	cyclosporine	47	49	false	none	7.14 Carbamazepine    Verapamil therapy may increase carbamazepine concentrations during combined therapy.  This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.  7.15 Cyclosporine    Verapamil therapy may increase serum levels of cyclosporine.  		2002	3008	D002220	D016572
digitalis	metoprolol	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		none	6918	none	D008790
digitalis	metoprolol	20	18	false	none	A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.  A variable effect has been seen when verapamil and atenolol were given together.  7.4 Digitalis    Consider reducing digoxin dose when verapamil and digoxin are to be given together.  		none	6918	none	D008790
rifampin	Theophylline	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		9384	10438	9384	D013806
rifampin	Theophylline	58	59	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		9384	10438	9384	D013806
rifampin	telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	274786	9384	274786
rifampin	telithromycin	4	3	false	none	Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	274786	9384	274786
rifampin	Phenobarbital	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	8134	9384	D010634
rifampin	Phenobarbital	58	57	false	none	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  		9384	8134	9384	D010634
rifampin	erythromycin	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	4053	9384	D004917
rifampin	erythromycin	4	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.  		9384	4053	9384	D004917
rifampin	Cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		9384	2541	9384	2541
rifampin	Cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		9384	2541	9384	2541
ethanol	Clonidine	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		448	2599	D000431	D003000
ethanol	Clonidine	27	29	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  		448	2599	D000431	D003000
ethanol	Clonidine	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		448	2599	D000431	D003000
ethanol	Clonidine	27	28	false	none	7.5 Alcohol    Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.  7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  		448	2599	D000431	D003000
Clonidine	telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
Clonidine	telithromycin	29	30	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
Clonidine	telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
Clonidine	telithromycin	28	30	false	none	7.6 Clonidine    Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil.  Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  		2599	274786	D003000	274786
Clonidine	doxorubicin	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		2599	3639	D003000	3639
Clonidine	doxorubicin	29	31	false	none	Monitor heart rate in patients receiving concomitant verapamil and clonidine.  7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		2599	3639	D003000	3639
Theophylline	Phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	8134	D013806	D010634
Theophylline	Phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  		10438	8134	D013806	D010634
Theophylline	Cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		10438	2541	D013806	2541
Theophylline	Cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.  		10438	2541	D013806	2541
telithromycin	procarbazine	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	8702	274786	8702
telithromycin	procarbazine	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	8702	274786	8702
telithromycin	doxorubicin	30	31	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		274786	3639	274786	3639
telithromycin	doxorubicin	30	31	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  		274786	3639	274786	3639
telithromycin	erythromycin	3	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	4053	274786	D004917
telithromycin	erythromycin	3	2	false	none	Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.  Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.  		274786	4053	274786	D004917
telithromycin	prednisone	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	8640	274786	D011241
telithromycin	prednisone	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	8640	274786	D011241
telithromycin	oncovin	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	11202	274786	D014750
telithromycin	oncovin	30	32	false	none	7.7 Telithromycin    Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics.  7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		274786	11202	274786	D014750
paclitaxel	procarbazine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		56946	8702	56946	8702
paclitaxel	procarbazine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		56946	8702	56946	8702
paclitaxel	Quinidine	33	34	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		56946	9068	56946	9068
paclitaxel	Quinidine	33	34	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		56946	9068	56946	9068
paclitaxel	Quinidine	33	35	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		56946	9068	56946	9068
paclitaxel	Quinidine	33	35	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy.  		56946	9068	56946	9068
paclitaxel	doxorubicin	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		56946	3639	56946	3639
paclitaxel	doxorubicin	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		56946	3639	56946	3639
paclitaxel	prednisone	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		56946	8640	56946	D011241
paclitaxel	prednisone	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		56946	8640	56946	D011241
paclitaxel	oncovin	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		56946	11202	56946	D014750
paclitaxel	oncovin	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  		56946	11202	56946	D014750
procarbazine	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		8702	9068	8702	9068
procarbazine	Quinidine	32	34	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		8702	9068	8702	9068
procarbazine	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		8702	3639	8702	3639
procarbazine	doxorubicin	32	31	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		8702	3639	8702	3639
procarbazine	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		8702	8640	8702	D011241
procarbazine	prednisone	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		8702	8640	8702	D011241
procarbazine	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		8702	11202	8702	D014750
procarbazine	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		8702	11202	8702	D014750
Quinidine	prednisone	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	8640	9068	D011241
Quinidine	prednisone	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	8640	9068	D011241
Quinidine	oncovin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11202	9068	D014750
Quinidine	oncovin	34	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.  		9068	11202	9068	D014750
doxorubicin	prednisone	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3639	8640	3639	D011241
doxorubicin	prednisone	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3639	8640	3639	D011241
doxorubicin	oncovin	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3639	11202	3639	D014750
doxorubicin	oncovin	31	32	false	none	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		3639	11202	3639	D014750
prednisone	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		8640	11202	D011241	D014750
prednisone	oncovin	32	32	false	none	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  		8640	11202	D011241	D014750
